...
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >LIK066 (LICOGLIFLOZIN), AN SGLT1/2 INHIBITOR, ROBUSTLY DECREASES ALT AND IMPROVES MARKERS OF HEPATIC AND METABOLIC HEALTH IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: INTERIM ANALYSIS OF A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2a STUDY
【24h】

LIK066 (LICOGLIFLOZIN), AN SGLT1/2 INHIBITOR, ROBUSTLY DECREASES ALT AND IMPROVES MARKERS OF HEPATIC AND METABOLIC HEALTH IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: INTERIM ANALYSIS OF A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2a STUDY

机译:Lik066(Licogliflozin),SGLT1 / 2抑制剂,鲁棒地降低ALT,改善了非酒精性脂肪肝病患者的肝癌和代谢健康的标志:临时分析12周,随机,安慰剂控制,相2A研究

获取原文
获取原文并翻译 | 示例
           

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号